Craig-Hallum Maintains Clover Health(CLOV.US) With Buy Rating
CCORF Maintains Clover Health(CLOV.US) With Buy Rating, Maintains Target Price $4.5
Craig-Hallum Maintains Clover Health(CLOV.US) With Buy Rating
Clover Health Investments (CLOV) Receives a Buy From Craig-Hallum
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Clover Health Investments (CLOV) and Pacira Pharmaceuticals (PCRX)
Leerink Partners Maintains Clover Health(CLOV.US) With Hold Rating, Cuts Target Price to $4
Cautious Outlook for Clover Health: Hold Rating Amid Growth and Profitability Challenges
Craig-Hallum Maintains Clover Health(CLOV.US) With Buy Rating, Announces Target Price $6
Craig-Hallum Keeps Their Buy Rating on Clover Health Investments (CLOV)
Clover Health Investments Is Maintained at Buy by Canaccord Genuity
Clover Health Investments Price Target Raised to $4.50/Share From $4.20 by Canaccord Genuity
Clover Health Investments Analyst Ratings
CCORF Maintains Clover Health(CLOV.US) With Buy Rating, Raises Target Price to $4.5
Craig-Hallum Maintains Clover Health(CLOV.US) With Buy Rating
UBS Upgrades Clover Health(CLOV.US) to Hold Rating, Raises Target Price to $4.5
Craig-Hallum Maintains Clover Health(CLOV.US) With Buy Rating
Craig-Hallum Maintains Clover Health(CLOV.US) With Buy Rating
Craig-Hallum Maintains Clover Health(CLOV.US) With Buy Rating
Craig-Hallum Maintains Clover Health(CLOV.US) With Buy Rating
Clover Health Investments Analyst Ratings